Latest news with #BrazilianReal
Business Standard
21-05-2025
- Business
- Business Standard
Torrent Pharma gains as Q4 PAT rises 11% YoY to Rs 498 cr; recommends final dividend of Rs 6/sh
Torrent Pharmaceuticals added 1.53% to Rs 3,292.95 after the company's consolidated net profit increased 10.91% to Rs 498 crore in Q4 FY25 as against Rs 449 crore posted in Q4 FY24. Total revenue from operations grew 7.79% year on year (YoY) to Rs 2,959 crore in the quarter ended 31 March 2025. Profit before tax stood at Rs 665 crore in March 2025 quarter, up 5.38% from Rs 631 crore posted in same quarter last year. Operating EBITDA stood at Rs 964 crore in Q4 FY25, registering a growth of 9.17% as against Rs 883 crore reported in Q4 FY24. The operating EBITDA margin improved to 32.6% in Q4 FY25, up from 32.2% in the previous year. Torrent Pharmaceuticals reported India revenues of Rs 1,545 crore in Q4 FY25, marking a 12% year-on-year growth, driven by strong performance in focus therapies. According to AIOCD secondary market data, the Indian Pharmaceutical Market (IPM) grew 8% during the quarter. Torrent's chronic segment outpaced the market, posting a 14% growth compared to IPMs 9% rise in the same category. On a MAT (Moving Annual Total) basis, Torrent continued to outperform the industry across key therapy areas, supported by robust new product launches. The company currently has 21 brands ranked among the Top 500 in the IPM, with 14 brands clocking over Rs 100 crore in annual sales. Brazil revenues for Torrent Pharma stood at Rs 351 crore, marking a decline of 6%, primarily impacted by the steep depreciation of the Brazilian Real (BRL). However, constant currency revenues were $ 234 million, reflecting a 5% increase. The company also faced a challenge due to a lower-than-expected annual price increase on April 1st, which led wholesalers to reduce their inventory more than usual. According to IQVIA data, Torrent grew at 13%, outperforming the market's growth of 7%. Additionally, Torrent currently has sixty-three products under review by ANVISA. The company reported revenues of Rs 286 crore from its Germany operations in Q4 FY25, registering a 2% year-on-year growth. In constant currency terms, revenues stood at 31 million, up 1% YoY. The company attributed the modest growth to continued success in securing new tender wins, supported by ongoing cost improvement initiatives. Torrent Pharmaceuticals reported a 15% year-on-year rise in US business revenue at Rs 302 crore for Q4 FY25. In constant currency terms, revenue stood at $35 million, marking a 10% increase compared to the same period last year. On a full year basis, the companys net profit rallied 15.39% to Rs 1,911 crore on 7.34% rise in total revenue from operations to Rs 11,516 crore in FY25 over FY24. Torrent Pharmaceuticals reported strong performance in its India business for FY25, with revenues rising 13% year-on-year to Rs 6,393 crore. In Brazil, revenue declined 2% to Rs 1,100 crore; however, in constant currency terms, it grew 9% to R$734 million. The Germany business posted a 6% increase in revenue to Rs 1,139 crore, with constant currency growth of 5% at 126 million. Meanwhile, the US business recorded a 2% rise in revenue to Rs 1,100 crore. In constant currency, US revenue stood at $130 million, with flat growth of 1% after adjusting for one-off income in FY24. Meanwhile, the board recommended a final dividend of Rs 6 per equity share of Rs 5 each. Earlier an interim dividend of Rs 26 per equity share was paid during the last quarter, it added. Further, the board has approved the appointment of Aman Mehta as Managing Director, effective 1st August 2025. Lastly, the company said its board has recommended that members seek enabling approval to raise up to Rs 5,000 crore through the issuance of equity shares, including via convertible bonds/debentures, through qualified institutional placement (QIP) or any other modes at the upcoming annual general meeting. Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.
Economic Times
20-05-2025
- Business
- Economic Times
Torrent Pharmaceuticals Q4 Results: Net profit rises 11% to Rs 498 crore
Torrent Pharmaceuticals Ltd on Tuesday reported an 11 per cent rise in consolidated net profit at Rs 498 crore in the fourth quarter ended March 2025. The company, which had posted a consolidated net profit of Rs 449 crore in the corresponding quarter previous fiscal, announced the appointment of Aman Mehta -- elder son of Torrent Group Chairman Samir Mehta -- as Managing Director, effective August 1, 2025 as part of its succession planning. ADVERTISEMENT Consolidated total revenue from operations in the fourth quarter stood at Rs 2,959 crore as against Rs 2,745 crore in the same period a year ago, Torrent Pharmaceuticals Ltd said in a regulatory filing. Total expenses in the fourth quarter were higher at Rs 2,252 crore as compared to Rs 2,145 crore in the year-ago period, it added. During the quarter, the company said it had an exceptional item outgo of Rs 24 crore to settle a litigation over alleged price overcharging and demand raised by the National Pharmaceutical Pricing Authority (NPPA) in 2017. In the fourth quarter, India revenue was at Rs 1,545 crore, up 12 per cent led by outperformance in focus therapies. On the other hand, Brazil revenue was at Rs 351 crore, down 6 per cent, impacted by steep Brazilian Real (BRL) depreciation, it added. US business revenue was at Rs 302 crore, up by 15 per cent, and Germany revenue was up 2 per cent at Rs 286 crore, the company said. ADVERTISEMENT For fiscal 2024-25, consolidated net profit was at Rs 1,911 crore as against Rs 1,656 crore in 2023-24, the company said. FY25 consolidated total revenue from operations stood at Rs 11,516 crore as against Rs 10,728 crore in FY24, it added. ADVERTISEMENT Torrent Pharma said its board has recommended the members to obtain enabling approval to raise up to Rs 5,000 crore through issuance of equity shares, including via convertible bonds/debentures through Qualified Institutional Placement (QIP) and or any other modes in the upcoming Annual General Meeting. The board also recommended a final dividend of Rs 6 per equity share of Rs 5 each. Earlier an interim dividend of Rs 26 per equity share was paid during the last quarter, it added. (You can now subscribe to our ETMarkets WhatsApp channel)
Yahoo
04-04-2025
- Business
- Yahoo
Borderless.xyz adds BRLA to stablecoin network
Payments infrastructure firm has added BRLA, a provider of payment and stablecoin solutions in Brazil, to its stablecoin orchestration network. This collaboration will facilitate access to BRLA's local payment rails through platform. With this move, the company aims to create a network connecting stablecoin companies and local payment systems, enabling seamless integration of on-chain and off-chain finances. This partnership is expected to enhance the financial infrastructure in Brazil by providing choices for counterparties involving stablecoins. CEO Kevin Lehtiniitty said: 'Brazil is a key market where stablecoins make remittances faster and cheaper. BRLA is a leader in payments in the region and the only issuer of an independently audited BRL stablecoin. I'm really excited to bring their local rails to stablecoin companies around the world through the Network.' BRLA Digital co-founder Lucas Giorgio said: 'At BRLA, we're building the most reliable infrastructure for stablecoin access and local payments in Brazil. Partnering with allows us to bring that infrastructure to a truly global stage, connecting with the best-in-class stablecoin companies. Together, we're making it easier for the world to access the regions financial system through the best-in-market product—designed for scale, built for compliance, and trusted by companies moving real volume.' BRLA, operating within Brazil, is an issuer of independently audited Brazilian Real (BRL) stablecoin. The company's infrastructure supports the integration of stablecoin technology into local payment systems. Last month, partnered with USDM issuer Mountain Protocol to demonstrate the potential of yield-bearing stablecoins in transforming the payment landscape and creating new financial opportunities on a global scale. operates in over 50 countries, dealing with 23 different currencies, and facilitates transactions with internet-native money, including stablecoins and real-world assets. " adds BRLA to stablecoin network " was originally created and published by Electronic Payments International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
04-04-2025
- Business
- Yahoo
Borderless.xyz adds BRLA to stablecoin network
Payments infrastructure firm has added BRLA, a provider of payment and stablecoin solutions in Brazil, to its stablecoin orchestration network. This collaboration will facilitate access to BRLA's local payment rails through platform. With this move, the company aims to create a network connecting stablecoin companies and local payment systems, enabling seamless integration of on-chain and off-chain finances. This partnership is expected to enhance the financial infrastructure in Brazil by providing choices for counterparties involving stablecoins. CEO Kevin Lehtiniitty said: 'Brazil is a key market where stablecoins make remittances faster and cheaper. BRLA is a leader in payments in the region and the only issuer of an independently audited BRL stablecoin. I'm really excited to bring their local rails to stablecoin companies around the world through the Network.' BRLA Digital co-founder Lucas Giorgio said: 'At BRLA, we're building the most reliable infrastructure for stablecoin access and local payments in Brazil. Partnering with allows us to bring that infrastructure to a truly global stage, connecting with the best-in-class stablecoin companies. Together, we're making it easier for the world to access the regions financial system through the best-in-market product—designed for scale, built for compliance, and trusted by companies moving real volume.' BRLA, operating within Brazil, is an issuer of independently audited Brazilian Real (BRL) stablecoin. The company's infrastructure supports the integration of stablecoin technology into local payment systems. Last month, partnered with USDM issuer Mountain Protocol to demonstrate the potential of yield-bearing stablecoins in transforming the payment landscape and creating new financial opportunities on a global scale. operates in over 50 countries, dealing with 23 different currencies, and facilitates transactions with internet-native money, including stablecoins and real-world assets. " adds BRLA to stablecoin network " was originally created and published by Electronic Payments International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
28-03-2025
- Business
- Yahoo
Is Ambev (ABEV) The Top High Dividend Yielding Consumer Defensive Stock To Buy?
We recently published a list of . In this article, we are going to take a look at where Ambev S.A. (NYSE:ABEV) stands against other top high dividend yielding consumer defensive stocks to buy. Consumer defensive stocks tend to perform well in uncertain times because they sell essential items such as household products, healthcare items, and food and beverages, among others. Such companies also tend to have a strong pricing power which helps them to easily pass on increasing costs to consumers. The US market continues to struggle due to concerns over tariffs, geopolitical issues, and politics. In such times, consumer defensive stocks offer a way to protect one's portfolio from this uncertainty. When such shares also offer a high dividend yield, it performs a killer combination, loved by defensive investors looking to park their money for reliable passive income. We therefore decided to come up with a list of the top 10 high-dividend-yielding consumer defensive stocks. To come up with the list of top 10 high-dividend consumer defensive stocks, we only considered stocks from the consumer defensive sector with a market cap of at least $10 billion and a dividend yield of at least 4%. A close-up on several cans of freshly brewed beer in a commercial brewery. Ambev S.A. (NYSE:ABEV) is the producer, distributor, and seller of draft beer, malt and food, beer, carbonated soft drinks, non-alcoholic and non-carbonated products, and other alcoholic beverages. Ambev S.A. (NYSE:ABEV) is currently trading at a dividend yield of 5.53%. The company reiterated its resolve to continue this payout last year when it allocated R$2 billion in share repurchases and R$6.7 billion in dividends last year. Moreover, according to 19 different analyst ratings, ABEV has the highest target price of $5, which means it could be more than double from the current levels if the bull thesis plays out. Moving forward, Ambev S.A. (NYSE:ABEV) expects the cost of goods sold to grow between 5.5% and 8.5% due to the decrease in the Brazilian Real's purchasing power and higher aluminum costs. CEO Lisboa said the firm will focus on enhancing pricing strategies to drive margin expansion, though ideally it will want the currency headwinds to subside for a more predictable business performance. Overall, ABEV ranks 3rd on our list of top high dividend yielding consumer defensive stocks to buy. While we acknowledge the potential of ABEV as a leading investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as ABEV but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at .
